Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THR-317 in Diabetic Macular Oedema
NCT03071068Phase 2Completed
- Sponsor
- Oxurion
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of THR-317 in diabetic macular edema (DME), sponsored by Oxurion. Started Dec 2016; status: completed.
02
Drugs
THR-317
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03071068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071068.